Reference Range: |
Long-acting repeatable (LAR) dose-response levels: mean octreotide
level + or - 2 SD for patients on octreotide LAR for 3 or more months
(steady-state). The following represent trough levels measured
immediately before an injection of LAR.
10 mg/month: 1,153 + or - 748 pg/ml
20 mg/month: 2,518 + or - 1,020 pg/ml
30 mg/month: 5,241 + or - 3,004 pg/ml
60 mg/month: 10,926 + or - 5,530 pg/ml |
Comments: |
Contact Commercial Mailouts at 356-8593 to obtain collection tubes for
this testing. No other specimen collection container is acceptable by
the reference laboratory.
This test is useful only for those patients being treated with
octreotide acetate. No special preparation is needed for this test. For
optimal results, blood for this test should be drawn immediately before
the patient's next injection of octreotide LAR (trough levels).
Clinical Significance:
Octreotide (Sandostatin, Novartis Pharmaceutical Company) is used for
the control of symptoms associated with functional neuroendocrine
tumors. Frequent measurement of the octreotide levels may be useful in
guiding therapy in patients with poorly controlled symptoms or those
patients experiencing tumor growth during LAR therapy. Octreotide
levels in blood need to be in a specific range to be effective.
Measuring octreotide immediately prior to the monthly LAR injection
will determine trough levels of the drug in your blood. |